Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (467) clinical trials

Trial of Carfilzomib Lenalidomide Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Primary Objective: To compare progression free survival between Kyprolis (Carfilzomib), Revlimid (lenalidomide), Dexamethasone (KRd) arm and lenalidomide arm Secondary Objectives To determine the rate of minimal residual negative disease (MRD) at 6 and 12 months after randomization To compare the efficacy (rate of partial response, very good partial response, complete ...

Phase

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

The investigators propose to contact and interact with all patients with plasma cell dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical Center) for both surveillance and research purposes in order to develop interventions targeted to decrease their morbidity and mortality.

Phase N/A

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple myeloma (MM) is a malignancy of plasma cells, which remains a clinical challenge despite advanced therapeutic interventions including novel molecular therapies and stem cell transplantation (SCT). This trial is to test the safety and efficacy of T cells genetically modified to specifically target several MM surface antigens, including BCMA, ...

Phase

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

This is a multicenter, single arm, open-label phase 2 study. Approximately 38 subjects will be enrolled to receive daratumumab + dexamethasone. Treatment cycles have duration of 28 days. Subjects will receive treatment until disease progression, death, unacceptable toxicity or for a maximum of 30 months. Drug administration and follow-up visits ...

Phase

Study of Initial Treatment With Elotuzumab Carfilzomib Lenalidomide and Dexamethasone in Multiple Myeloma

Primary Objective The primary efficacy endpoint will be the rate of sCR and/or the rate of negative MRD by next generation gene sequencing (NGS) by clonoSIGHT (Adaptive Biotechnologies) at the end of 8 cycles among non-transplant candidates and transplant candidates who agreed to defer transplant Secondary Objectives To evaluate the ...

Phase

Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.

Hypothesis: We expect that patients who are classified, as high risk according to the ROADMAP-CAT-MM will experience symptomatic VTE more frequently and will have higher morbidity and mortality rates during the follow-up. The prospective validation of the ROADMAP-CAT-MM (combined or not with biomarkers of hypercoagulability) will allow to identify patients ...

Phase N/A

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

The investigators hypothesize that conformal radiation will allow the administration of higher doses of external beam radiation to marrow based malignancies than total body irradiation (TBI)without increasing the toxicity to normal tissues beyond that induced by TBI. Further,the investigators hypothesize that this will result in an improvement in disease response ...

Phase

Microtransplantation Versus Auto-SCT in PR Multiple Myeloma Patients

NDMM patients induction therapy with 4 cycles PCD/PAD regimen, achieve PR, eligible for SCT, were randomly divided into two arms. One arm receive microtransplantation, and the other accept auto-SCT. Comparison of the efficacy and safety of two arms, 2-year PFS and OS were also been observed. Clear the above program ...

Phase N/A

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Despite advances has been made to date in the treatment of patients with hematologic malignancies, clinical trials targeting solid cancers have achieved limited efficacy. One important reason is due to lack of ideal cancer antigens. NY-ESO-1 is expressed in various types of cancers, including neuroblastoma, hepatoma, myeloma, melanoma, esophagus, prostate, ...

Phase

The Effects of Huang-Lian-Jie-Du-Tang HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy

To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy.

Phase